A Study of NST-628 in Recurrent Grade 4 Glioma

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This is an open-label, single arm, non-randomized, Phase 0 and expansion Phase 1 study of NST-628 in adult patients with recurrent Grade 4 glioma with high phosphorylated extracellular signal-regulated kinase (pERK) expression who are scheduled for surgical resection. This study will evaluate the pharmacokinetics (PK), pharmacodynamics (PD), safety and tolerability, and anti-tumor activity of NST-628.
Epistemonikos ID: a821b1f2735e3c648a078be51e4b87ba9ce00c28
First added on: Aug 26, 2026